Intravitreal Bevacizumab for Diabetic Macular Edema
Sponsor
Isfahan Ophthalmology Research Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT00703235
Collaborator
(none)
Study Details
Study Description
Brief Summary
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.
This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2/Phase 3 |
Study Design
Study Type:
Interventional
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Diabetes mellitus
-
Clinically significant macular edema
-
Possibility of performing macular OCT
-
Consent of patient for inclusion in the study
Exclusion Criteria:
-
History of macular photocoagulation in less than 6 months of inclusion in the study
-
Necessity of surgical intervention
-
Rejection of the remaining in the study by patient
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Isfahan Ophthalmology Research Center
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00703235
Other Study ID Numbers:
- MUI - clinical - 185290
First Posted:
Jun 23, 2008
Last Update Posted:
Jun 23, 2008
Last Verified:
Jun 1, 2008